'Trial design' diaporamas de présentation

WHY BAYES? INNOVATIONS IN CLINICAL TRIAL DESIGN & ANALYSIS

1.69k views • 153 slides

Trial design : who and what

Highlights on Non Small Cell Lung Cancer Management Rome, October 29 , 2010. Trial design : who and what. Maria Carmela Piccirillo Clinical Trials Unit National Cancer Institute Naples. Gli studi di fase 2 randomizzati:. non possono essere formalmente comparativi;

1.02k views • 89 slides

CONSORT-EHEALTH

CONSORT-EHEALTH. Consolidated standards for reporting ehealth / mhealth trials. G. Eysenbach MD MPH FACMI Editor-in-Chief, J Med Internet Res Publisher, JMIR Publications Centre for Global eHealth Innovation University of Toronto, Dept of Health Policy, Management and Evaluation.

1.33k views • 88 slides

GLP-1 and use with insulin

742 views • 43 slides

Voriconazole NDAs 21-266 and 21-267 Empiric Antifungal Therapy of Febrile Neutropenic Patients Study 603

Voriconazole NDAs 21-266 and 21-267 Empiric Antifungal Therapy of Febrile Neutropenic Patients Study 603. John H. Powers, M.D. Medical Officer Division of Special Pathogen and Immunologic Drug Products Center for Drug Evaluation and Research. Introduction.

710 views • 34 slides

DESERT ( D rug- E luting S tent E vent R egistry of T hrombosis)

DESERT ( D rug- E luting S tent E vent R egistry of T hrombosis). The International FDA approved DES Thrombosis Registry. Ron Waksman, MD and Martin Leon, MD On Behalf of the DESERT Investigators. Grant/Research Support Consulting Fees/Honoraria. Volcano Medtronic Vascular

397 views • 27 slides

PUMPKINS FOR YOU

PUMPKINS FOR YOU. Highlights from the 2011 Pumpkin Variety Evaluations. Robert J. Precheur, James R. Jasinski , R. M. Riedel, Landon H. Rhodes, Marie Buerlson , Rachael Pack, Clarence Renk , Joe Davlin and Michael Haddix .

352 views • 25 slides

429 views • 19 slides

Frances M Cowan

Estimation of the HIV care cascade for female sex workers in Zimbabwe: Baseline results of the SAPPH-IRe Trial. Frances M Cowan. Collaborative project. Zimbabwe Ministry of Health and Child Care and Centre for Sexual Health and HIV AIDS Research, Zimbabwe,

364 views • 19 slides

Results of the Phase 3 Clinical Trials of Abraxane vs. Taxol in Metastatic Breast Cancer

In Metastatic Breast Cancer Abraxane Has Greater Anti-tumor Activity Than Taxol. Results of the Phase 3 Clinical Trials of Abraxane vs. Taxol in Metastatic Breast Cancer. William J. Gradishar, MD, FACP Professor of Medicine Northwestern University.

1.05k views • 16 slides

Vorapaxar for Secondary Prevention in Patients with Prior Myocardial Infarction

331 views • 16 slides

Study design and Levels of Evidence

Study design and Levels of Evidence. Dr Rafael Perera Director of Research Methods. Research questions. determine problem ( case reports/case-series , ecological/cross-sectional studies ) design interventions

1.21k views • 15 slides

The MONET trial 96 week analysis: darunavir/r monotherapy versus darunavir/r + 2NRTIs, for patients with HIV RNA < 5

The MONET trial 96 week analysis: darunavir/r monotherapy versus darunavir/r + 2NRTIs, for patients with HIV RNA < 50 copies/mL at baseline. Armin Rieger, Denes Banhegyi, Wolfgang Schmidt, Jose Arribas, Andrew Hill, Yvonne Van Delft, Christiane Moecklinghoff

288 views • 15 slides

Africa RISING WA Project - from the start until today

Africa RISING WA Project - from the start until today. I. Hoeschle-Zeledon Africa RISING Coordinator Stakeholder meeting Accra, Ghana, 23 January 2013.

279 views • 15 slides

INCLUSION/EXCLUSION CRITERIA

INCLUSION/EXCLUSION CRITERIA. 1. The following are considerations when defining the cardiac arrest trial patient population (i.e., the inclusion/exclusion criteria): The defined trial population can support a reasonable enrollment rate;

842 views • 14 slides

Demonstration Qualifying Action

Demonstration Qualifying Action. Charles Hargreaves 4 September 2007. The aim of Demonstration Qualifying Action. To encourage the suppliers to trial new measures Give the suppliers freedom to run trials on measures without an energy/carbon saving

240 views • 13 slides

The Role of Patient Advocates in Research

4 th Annual Medical Research Summit April 22, 2004. The Role of Patient Advocates in Research. Deborah E . Collyar PAIR: Patient Advocates In Research InterSPORE Patient Advocate/Research Team (PART) Program. Why Advocates In Research?. Bridging the Research Gap

289 views • 12 slides

Lonial S et al. Proc ASH 2013;Abstract 285.

Prolonged Survival and Improved Response Rates with ARRY-520 (Filanesib) in Relapsed/Refractory Multiple Myeloma (RRMM) Patients with Low a -1 Acid Glycoprotein (AAG) Levels: Results from a Phase 2 Study. Lonial S et al. Proc ASH 2013;Abstract 285. Background.

309 views • 12 slides

BARI 2D

BARI 2D. Mortality: 11.7% with revasc. vs. 12.2% with medical therapy; 11.8% with insulin-sensitization vs. 12.1% with insulin-provision PCI stratum, MACE: 23.0% with revasc. vs. 21.1% with medical therapy (p = 0.15)

289 views • 1 slides

SAPPHIRE: 3-Year Results

SAPPHIRE: 3-Year Results. Death, stroke, or MI at 30 days plus death or ipsilateral stroke between 31 days to 3 years: 24.6% for stent and 26.9% for CEA (p = 0.71) Mortality to 3 years: 20.0% versus 24.2% (p = 0.68), respectively Stroke to 3 years: 10.1% versus 10.7% (p = 0.77), respectively .

66 views • 1 slides